Dylan Dupuis
Stock Analyst at Roth MKM
(2.67)
# 2,107
Out of 4,761 analysts
9
Total ratings
44.44%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.71 | +309.36% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $2.84 | +287.32% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $4.01 | +474.28% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $34.07 | -6.08% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $1.94 | +415.46% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.71
Upside: +309.36%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $2.84
Upside: +287.32%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $4.01
Upside: +474.28%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $34.07
Upside: -6.08%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $1.94
Upside: +415.46%